Cullinan Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	0	0	18.94	0	0	0
Gross Profit	0	0	18.94	0	0	0
Selling, General & Admin	42.49	40.19	29.15	17.12	5.48	5
Research & Development	148.16	91.95	57.75	43.21	16.79	9.58
Other Operating Expenses	0.44	-276.79	0	0	0	0
Operating Expenses	191.09	-144.65	86.9	60.34	22.27	14.59
Operating Income	-191.09	144.65	-67.95	-60.34	-22.27	-14.59
Other Expense / Income	-23.81	-8.69	-2.38	-8.54	-1.61	-0.4
Pretax Income	-167.28	153.34	-65.57	-51.8	-20.66	-14.19
Income Tax	-14.12	42.12	0	0	0	0
Net Income	-153.16	111.21	-65.57	-51.8	-20.66	-14.19
Shares Outstanding (Basic)	42	45	43	20	6	3
Shares Outstanding (Diluted)	42	47	43	20	6	3
Shares Change	-10.91%	8.27%	116.61%	210.86%	150.89%	-
EPS (Basic)	-3.69	2.46	-1.52	-2.60	-3.23	-5.56
EPS (Diluted)	-3.69	2.38	-1.52	-2.60	-3.23	-5.56
Free Cash Flow	-134.48	-127.71	-43.43	-29.78	-20.92	-13.81
Free Cash Flow Per Share	-3.24	-2.83	-1.01	-1.50	-3.27	-5.42
Gross Margin	-	-	100.00%	-	-	-
Operating Margin	-	-	-358.73%	-	-	-
Profit Margin	-	-	-346.14%	-	-	-
Free Cash Flow Margin	-	-	-229.28%	-	-	-
Effective Tax Rate	-	27.47%	-	-	-	-
EBITDA	-166.97	153.43	-65.52	-51.74	-20.59	-14.15
EBITDA Margin	-	-	-345.86%	-	-	-
Depreciation & Amortization	0.31	0.09	0.05	0.06	0.07	0.04
EBIT	-167.28	153.34	-65.57	-51.8	-20.66	-14.19
EBIT Margin	-	-	-346.14%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).